Skip to main content

Nasdaq News

3 Things to Watch in the Stock Market This Week

6 years 1 month ago
Stocks rose last week, as both the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) gained less than 0.5%. The boost was enough to put the Dow back into positive territory for the year while the S&P 500 is up about 8%.Earnings season hits a

This Social Security Move Could Increase Your Benefits Up to 77%

6 years 1 month ago
Social Security's trust funds will be exhausted by 2031, according to the Congressional Budget Office, necessitating substantial benefit cuts if the government doesn't reform the program before then. That makes it all the more important for you to make smart choices to maximize y

Better Buy: Costco vs. Procter & Gamble

6 years 1 month ago
Procter & Gamble (NYSE: PG) and Costco Wholesale (NASDAQ: COST) perform fundamentally different functions. P&G produces personal care products, and Costco is one of its numerous retailers.However, both are large-cap stocks supported by mature companies that deliver rising

Netflix Has Raised Prices in 2 Countries -- Is the U.S. Next?

6 years 1 month ago
After boosting prices for its basic and standard plans in Australia last month, Netflix (NASDAQ: NFLX) made a similar move in Canada this month, increasing the cost of the standard and premium tiers. The bumps ranged from 1 to 2 dollars in local currency. Management is always eva

Is Tesla Stock a Buy Ahead of Earnings?

6 years 1 month ago
On Wednesday, Tesla (NASDAQ: TSLA) will report its third-quarter results. After announcing record third-quarter deliveries, expectations for the electric-car maker's financial performance during the period are high. Even more, a soaring stock price over the past year has raised t

Is AMC Entertainment a Buy?

6 years 1 month ago
Hollywood is leaving AMC Entertainment (NYSE: AMC) behind. One movie studio after another is postponing the debut of its feature films until 2021, leaving little more than reruns for movie theaters to show.Regal Theaters parent Cineworld chose to reclose all of its theaters for t

Claiming Social Security Benefits Early Could Cost You $35,500

6 years 1 month ago
When it comes to choosing when to begin claiming Social Security benefits, you have a few options. The earliest you can file is age 62, but you could also wait to claim at any age thereafter. If you wait until age 70 or beyond to begin claiming, you'll receive the highest possibl

Amazon Earnings: What to Watch on Thursday, Oct. 29

6 years 1 month ago
Amazon.com (NASDAQ: AMZN) is slated to report its third quarter 2020 results after the market close on Thursday, Oct. 29.The e-commerce and technology giant is barreling toward its report on a strong note. In the second quarter, the company trounced Wall Street's estimates for bo

3 Best Dividend Stocks to Buy Ahead of the Election

6 years 1 month ago
Elections can bring big changes, since that's usually what's on the ballot. Because of that, there's always a lot of uncertainty leading up to election day as the outcome can set a new course for the country. That can make it harder to invest because some changes can impact busin

Goldman Sachs: 2 Stocks That Could Climb Over 90%

6 years 1 month ago

What’s more critical for the stock market’s health than the outcome of the presidential election? A COVID-19 vaccine, so says Goldman Sachs.  

With Q3 earnings season kicking into gear this week, the firm believes the virus’ effect on fundamentals should be the focus, as opposed to the race to the White House. “The vaccine represents a more important factor than the election result for the path of equities... The consequences of the semi-frozen economy on an uneven road to recovery will be in Q3 results,” Goldman Sachs’ U.S. equity strategist David Kostin commented. 

Even though elections are a source of uncertainty, research analysts from Goldman Sachs found just a 4% difference in EPS if President Trump is re-elected or the Democrats come out on top. Based on the firm’s analysis, an increase in fiscal spending that is partly funded by increased tax revenue would “boost economic growth, and help offset the earnings headwind from high tax rates.” 

Taking this into consideration, our attention turned to two stocks that Goldman Sachs thinks have outsized growth prospects, with the firm’s analysts forecasting at least 90% upside potential for each. Using TipRanks’ database, we found out both tickers also sport a “Strong Buy” consensus rating from the rest of the Street. 

Athira Pharma (ATHA) 

Applying cutting-edge approaches to neurodegenerative diseases, Athira Pharma wants to improve the lives of patients from all over the world. Given the potential of its asset in Alzheimer’s disease (AD), Goldman Sachs is pounding the table. 

ATHA made its public market debut on September 18, with the first trade coming in at 17.4% above the IPO price. Raising $204 million, the company sold 12 million shares instead of the 10 million that was originally expected.   

Writing for Goldman Sachs, analyst Graig Suvannavejh points to its lead candidate, ATH-1017, which is a small molecule activator of HGF/MET currently being evaluated in a Phase 2/3 trial as a treatment for mild-to-moderate AD, as a key component of his bullish thesis.  

The analyst doesn’t dispute that AD is a difficult indication to address, but tells clients he has high hopes for ATHA. “We’re fully cognizant of the history of AD drug development, and its well documented past of high failure rates. As such, AD-focused companies like ATHA should be considered as having high risk. However, as there still remains a significant lack of effective drugs for AD, we believe alternative approaches to treating AD have merit,” he explained. 

In the past, the most common therapeutic approaches to AD have been those focused on the belief that the accumulation of disease-causing proteins in the brain leads to AD. However, AD therapeutics based on targeting amyloid have all failed in clinical trials to demonstrate efficacy, with monoclonal antibody (mAb) approaches that target tau, another protein that aggregates in the brains of AD patients, also failing.  

So, ATHA’s differentiated approach makes it a stand-out, in Suvannavejh’s opinion. Looking at the therapy’s mechanism of action (MOA), it is based on HGF/MET agonism, a strategy that hasn’t been studied in AD before. Additionally, Suvannavejh argues the FDA’s recent decision to review Biogen’s aducanumab for approval even though it was prematurely discontinued in two large Phase 3 studies due to futility is a “sign of a positive regulatory backdrop.” 

On top of this, the company is applying a new thinking to AD clinical trials. It will use a non-traditional technique (EEG) in order to measure improvements in the brains of AD subjects, and a novel clinical trial end point (Global Statistical Test/GST) that will evaluate the efficacy. It is based on both the ERP biomarker and more traditional efficacy measures (e.g., ADAS-Cog). 

Weighing in on this, Suvannavejh stated, “With this entirely innovative way of thinking in mind, we think it’s critical to acknowledge that FDA has already provided its sign off to ATHA’s novel clinical trial plan — which importantly also reduces overall time and costs typically associated with AD drug development. Further, given our view that FDA may be experiencing a sense of urgency to get new AD therapeutics in the hands of patients, their caregivers and physicians, we believe the time is right for a candidate like ATH-1017.” 

When it comes to the revenue potential for ATH-1017, according to Suvannavejh, neurodegenerative diseases represent one of the highest areas of unmet medical need, with it estimated that more than 5 million people over the age of 65 in the U.S. have AD. This number is expected to nearly triple by 2050, based on research from the Alzheimer’s Association. To this end, the analyst projects risk-unadjusted peak 2035 sales of $10.8 billion. 

Everything that ATHA has going for it convinced Suvannavejh to initiate coverage with a Buy rating. In addition to the call, he set a $53 price target, suggesting 189% upside potential. (To watch Suvannavejh’s track record, click here) 

Judging by the consensus breakdown, opinions are anything but mixed. With 4 Buys and no Holds or Sells assigned in the last three months, the word on the Street is that ATHA is a Strong Buy. At $42.50, the average price target implies 132% upside potential. (See Athira Pharma stock analysis on TipRanks) 

Denali Therapeutics (DNLI) 

Dedicated to defeating neurodegenerative diseases through rigorous therapeutic development, Denali Therapeutics is attracting significant attention from Wall Street. Ahead of a key data readout, Goldman Sachs has high hopes.  

As the company gears up to report first proof-of-concept biomarker data for DNL310 in Hunter syndrome by YE20, the firm’s Salveen Richter likes what she’s seeing.  

DNL310 is a recombinant form of the iduronate 2-sulfatase (IDS) enzyme engineered to cross the blood-brain barrier (BBB) using Denali’s enzyme transport vehicle (ETV) technology, which enables the trafficking of large molecules into the brain.  

DNLI is set to publish initial data from Cohort A, and management expects the starting dose of 3mg/kg to reduce CSF GAGs by 50% at eight weeks. A second Cohort B will evaluate DNL310 in a broader range of patients, with dose escalation levels based on findings from Cohort A. Richter points out a 50% reduction in CSF GAGs was associated with a decrease in lipid lysosome and neurofilament light (NfL) chain accumulations that are associated with neuronal degeneration and injury. 

“While this is the first in-human trial for DNL310, we see the pre-clinical data as strongly supportive of the anticipated therapeutic benefit and potential for GAG reduction in the CSF to drive downstream changes in lysosomal lipid and NfL accumulation (i.e. prevent neuronal dysfunction and injury) for improved cognition and function,” Richter commented.  

It should be noted that the preclinical and early clinical data for JCR Pharmaceuticals’ JR-141, a BBB-penetrant fusion protein that also leverages receptor-mediated transcytosis to traffic iduronate-2-sulfatase (I2S) to the brain, de-risks the approach, in Richter’s opinion.  

To this end, the five-star analyst believes positive DNL310 biomarker data could serve as proof-of-concept for DNLI’s transport vehicle (TV) technology. The platform’s modularity could allow for various large molecules to be transported across the BBB, for a range of other neurodegenerative indications like Parkinson’s disease (PD) and frontotemporal dementia (FTD).  

On top of this, DNLI could leverage this delivery platform for antibodies, proteins or enzymes not currently in its own portfolio, with increasing interest on assets from Biogen, according to Richter.  

In line with her optimistic approach, Richter stayed with the bulls, reiterating a Buy rating. She also bumped up the price target from $41 to $60. Investors could be pocketing a gain of 36%, should this target be met in the twelve months ahead. (To watch Richter’s track record, click here) 

Looking at the consensus breakdown, 6 Buys and 2 Holds have been issued in the last three months. Therefore, DNLI gets a Strong Buy consensus rating. Based on the $51.17 average price target, shares could surge 16% in the next year. (See Denali Therapeutics stock analysis on TipRanks) 

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. 

Apple Makes Another Play for the Home

6 years 1 month ago
Apple (NASDAQ: AAPL) has dabbled in the smart home for years without making much headway. HomeKit was supposed to be the center of the smart home, but has lagged tech stock competitors in the number of compatible products available and is still a little clunky to use and setup. H

3 Things About Retirement Every Worker Needs to Know

6 years 1 month ago
Whether you're new to the workforce, midway through your career, or gearing up to leave the working world for good, you're no doubt aware that to retire comfortably, you'll need to plan and save in advance. But how much do you really know about retirement? Here are a few importan

2 Big Challenges As Tesla Aims for a $25,000 Car

6 years 1 month ago
Tesla (NASDAQ: TSLA) has set its sights on building an affordable car with a $25,000 starting price -- again. At the company's Battery Day last month, Tesla announced a slew of innovations designed to reduce battery production costs by up to 56% while also increasing range and po

3 Great Dividend Stocks Whose Payouts Could Double

6 years 1 month ago
Imagine if your paycheck doubled. Probably few of us have ever suddenly experienced this with our jobs, but it's something dividend investors can enjoy. If that intrigues you, read on to see why Wingstop (NASDAQ: WING), SS&C Technologies (NASDAQ: SSNC), and Domino's Pizza (NY
Checked
9 minutes 33 seconds ago
This feed is responsible for generating the rss feed related to the topic latest article
Subscribe to Nasdaq News feed